ADMA Biologics (NASDAQ:ADMA) Shares Gap Down - Should You Sell?

Shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Get Free Report) gapped down prior to trading on Friday . The stock had previously closed at $17.90, but opened at $17.16. ADMA Biologics shares last traded at $17.76, with a volume of 422,669 shares.

Wall Street Analyst Weigh In

ADMA has been the subject of a number of recent analyst reports. Cantor Fitzgerald reissued an "overweight" rating and issued a $20.00 price objective on shares of ADMA Biologics in a report on Friday, September 20th. Raymond James increased their price target on ADMA Biologics from $18.00 to $25.00 and gave the stock a "strong-buy" rating in a research note on Friday, November 8th. Finally, HC Wainwright lifted their price objective on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a "buy" rating in a research note on Friday, November 8th.

ADMA Biologics Stock Performance

The stock has a market cap of $4.11 billion, a P/E ratio of 62.14 and a beta of 0.70. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. The company has a fifty day moving average of $18.92 and a 200 day moving average of $16.25.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.15 EPS for the quarter, topping analysts' consensus estimates of $0.13 by $0.02. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The company had revenue of $119.84 million for the quarter, compared to the consensus estimate of $107.25 million. During the same quarter in the previous year, the business earned $0.01 EPS. On average, equities analysts predict that ADMA Biologics, Inc. will post 0.52 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Brad L. Tade sold 15,000 shares of the company's stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $21.15, for a total transaction of $317,250.00. Following the completion of the sale, the chief financial officer now directly owns 199,433 shares of the company's stock, valued at $4,218,007.95. This represents a 7.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 3.70% of the company's stock.

Institutional Trading of ADMA Biologics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Quest Partners LLC acquired a new stake in ADMA Biologics during the 2nd quarter valued at $29,000. Hollencrest Capital Management purchased a new position in shares of ADMA Biologics during the third quarter valued at $30,000. Larson Financial Group LLC purchased a new position in shares of ADMA Biologics during the third quarter valued at $31,000. National Bank of Canada FI acquired a new position in ADMA Biologics during the third quarter valued at $35,000. Finally, Harvest Fund Management Co. Ltd purchased a new stake in ADMA Biologics in the 3rd quarter worth about $62,000. Institutional investors and hedge funds own 75.68% of the company's stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.